Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | Zendy

Tony Mok | Zendy; YiLong Wu | Zendy; MyungJu Ahn | Zendy; Marina Chiara Garassino | Zendy; Hye Ryun Kim | Zendy; Suresh S. Ramalingam | Zendy; Frances A. Shepherd | Zendy; Yong He | Zendy; Hiroaki Akamatsu | Zendy; Willemijn S.M.E. Theelen | Zendy; Chee Khoon Lee | Zendy; Martin Sebastian | Zendy; Alison Templeton | Zendy; Helen Mann | Zendy; Marcelo Marotti | Zendy; Serban Ghiorghiu | Zendy; Vassiliki A. Papadimitrakopoulou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Author(s) -

Tony Mok,

YiLong Wu,

MyungJu Ahn,

Marina Chiara Garassino,

Hye Ryun Kim,

Suresh S. Ramalingam,

Frances A. Shepherd,

Yong He,

Hiroaki Akamatsu,

Willemijn S.M.E. Theelen,

Chee Khoon Lee,

Martin Sebastian,

Alison Templeton,

Helen Mann,

Marcelo Marotti,

Serban Ghiorghiu,

Vassiliki A. Papadimitrakopoulou

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1612674

Subject(s) - osimertinib , t790m , pemetrexed , lung cancer , medicine , epidermal growth factor receptor , oncology , tyrosine kinase inhibitor , tyrosine kinase , cancer research , chemotherapy , cancer , receptor , erlotinib , gefitinib , cisplatin

Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research